<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02855632</url>
  </required_header>
  <id_info>
    <org_study_id>SRRSHRMC2016001</org_study_id>
    <nct_id>NCT02855632</nct_id>
  </id_info>
  <brief_title>The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis</brief_title>
  <official_title>The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wenzhou people's hospital，zhejiang province,China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Women and Children's hospital，zhejiang province,China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sir Run Run Shaw Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of Granulocyte Colony Stimulating
      Factor(G-CSF) on decreasing adhesion reformation and improving fertility outcomes after
      hysteroscopic adhesiolysis in patients with moderate to severe intrauterine adhesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After hysteroscopic adhesiolysis, patients with moderate to severe intrauterine adhesions
      will be allocated into 2 groups randomly, with COOK ballon and estrogen and progesterone
      sequential therapy given to prevent adhesion routinely. 7 day later, G-CSF or normal saline
      will be injected into the uterine cavity by Tom catheter after removing the balloon
      respectively. A second hysteroscopic examination will be performed in 2 months to check up
      the adhesion reformation. In addition, the endometrial thickness after surgery and fertility
      outcome will be followed up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adhesion reformation rate</measure>
    <time_frame>2 months after first surgery</time_frame>
    <description>Adhesion reformation rate after first adhesiolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>3 years after first surgery</time_frame>
    <description>pregnancy rate after adhesiolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>4 years after first surgery</time_frame>
    <description>live birth rate after adhesiolysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>1 months after G-CSF injection</time_frame>
    <description>Endometrial thickness in the ovulation phase after G-CSF injection</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.</description>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>granulocyte colony-stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>0.9% NaCl</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hormone therapy</intervention_name>
    <description>In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.</description>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Artificial cycle</other_name>
    <other_name>Artificial menstrual cycle</other_name>
    <other_name>Estrogen and Progesterone Sequential Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cook balloon</intervention_name>
    <description>At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.</description>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate and severe intrauterine adhesion patients(AFS score ≥5)

          -  age 18-40

          -  first time receiving hysteroscopic adhesiolysis

          -  provided COOK balloon as adjuvant adhesion prevention treatment

          -  accepting randomized trial

        Exclusion Criteria:

          -  Mild adhesion patients

          -  uterine shape can't be restored in the end of surgery

          -  abnormal chromosome phenotype

          -  systemic disease

          -  no fertility desire

          -  contradiction of G-CSF injection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaona Lin, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Sir Run Run Shaw Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaona Lin, Doctor</last_name>
    <phone>+8657186006252</phone>
    <email>linna73@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310018</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yamei Xue, Master</last_name>
      <phone>+8657186002222</phone>
      <email>yaya7450@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Run Run Shaw Hospital</investigator_affiliation>
    <investigator_full_name>Xiaona Lin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>G-CSF</keyword>
  <keyword>adhesion reformation</keyword>
  <keyword>Asherman syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

